pharmedium option tabl
pharmedium mask strength underli core busi despit strength
abc core oper pharmedium major focu point today
call particularli manag indic conduct full scale review
busi could see full rang option increas invest
remedi issu even full sale busi howev self-
impos date expect complet remind acquir
pharmedium bln unclear could see similar return
busi sold given issu memphi facil also note
remain facil open cover fix expens whole
pharmedium busi may attribut enhanc qualiti
procedur facil reduc volum suggest
sell busi could actual accret earn memphi facil
remain close extend period exclud pharmedium busi
acquisitions/consolid compani oper profit grew mid-singl digit
rang result suggest gener deflat may stabil brand
inflat despit lower y/i basi bad fear
compani continu benefit larg anchor custom walgreen
rais ep larg beat abc guidanc rang
depend upon manag gener execut expens manag
synergi captur hd smith pricing/mix pharmedium despit remov
memphi facil still key variabl within rang follow today result
rais ep larg magnitud beat
rel expect period compani expect ep flat
year ago period back half year continu see better ep
growth given lap pharmedium maintain ew rate pt
base price-to-earnings multipl ep
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight gain
share via largest custom walgreen
compani continu face headwind throughout
relat gener price deflat
believ persist hamper ep growth
upsid case see modest multipl expans
gener price deflat come better fear
would lead improv ep
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
group
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
compani confirm expand relationship mar recal henri
schein recent announc mar would consolid veterinari purchas
competitor case mwi sale repres shift
expect mln per
regard pharmedium note compani put busi full
review option commit resourc busi move toward full
sale busi compani engag new cgmp consult firm help
remedi effort timelin complet review establish
growthmid singl digit mid singl digit oper expens growthmid singl digit growthtrack high end mid singl digit growthdistribut servic op profit growth mid singl digit growth singl digit growthoth op profit growthhigh singl digit growthhigh singl digit growthoper profit growth mid singl digit singl digit growthinterest y/yadj effect tax changebrand inflationmid-singl digit inflationmid-singl digit inflationgener deflationsimilar tail end tail end stabl nowbeliev stabl nowshar ep ep flat barclay corp
amerisourcebergen revenu profit model
 annual revenu model mil abcabcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom ebit barclay corp
 quarterli incom statement mil ep ep ep ep distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay corp
 annual revenu model mil abcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal ebit barclay corp
 annual incom statement distribut sell oper addback check excl intang asset ens rate interest ens check ep fulli dilut share growth distribut sell per barclay corp
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
